Cenix BioScience awarded major R&D grant for further development of its in vivo RNAi platform
On December 13th Cenix BioScience GmbH announced that it has secured a major research and development grant from the German state of Saxony, under a program administered by the Sächsische Aufbaubank (SAB). The 2-year grant totaling over 1.1 Mio Euro will support a project entitled "DARE™ delivery technology development".
For Cenix, this funding will help accelerate the internal build-up of new capabilities focusing on in vivo RNAi experimentation combining siRNA technology with novel delivery solutions including its own proprietary DARE™ technology. The R&D work comes as part of a major growth and diversification initiative ongoing since early 2008 to broaden the company's range of activities beyond the cell-based RNAi services that have established Cenix as a global leader in RNAi screening over the past 11 years.
Source: press relaese Cenix BioScience GmbH from 12/13/10
Contact
Cenix
Birte Sönnichsen, COO
Cenix BioScience GmbH
Tel: +49 (0) 351 4173-0
Email: info@cenix-bioscience.com
Web: www.cenix-bioscience.com